Int J Pharm Bio Sci Volume 7, Issue 3, 2016 (July-Sept), Pages:01-5
A COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF MOMETASONE FORMOTEROL AND BUDESONIDE FORMOTEROL AS COMBINATION THERAPY IN MODERATE BRONCHIAL ASTHMA PATIENTS-A PROSPECTIVE,OPEN LABEL COMPARATIVE STUDY
Fixed dose combination of an inhalational long acting beta-2 agonist with corticosteroids provide better
asthma control as they modify the pathophysiology of bronchial asthma, i.e. smooth muscle dysfunction and airway inflammation. Moreover, it minimizes systemic side effects and improves patient adherence rather than administering as monotherapy. This 12 week prospective comparative study was conducted to evaluate the efficacy and safety of mometasone / formoterol with budesonide / formoterol as combination therapy in 200 moderate bronchial asthma patients.. Group I patients received mometasone 400μg / formoterol 6μg and group II received budesonide 400 μg/ formoterol 6 μg for a period of 12 weeks. Forced expiratory volume in one second and asthma symptom score were used as outcome parameters.The FEV1 values and the symptom scoring were found to be improved in both the groups with mometasone group have shown a better improvement than the budesonide group and was statistically significant. The adverse reactions were mild and treated symptomatically.To conclude,the present study emphasized that inhalational mometasone combination is slightly superior to budesonide combination.